The Utility of Testing Serum C-reactive Protein and its Clinical Significance in COVID-19 Patients

The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes the current coronavirus disease 2019 (COVID-19) pandemic, which has disclosed alarming challenges to global health. The disease demonstrates several clinical issues, from mild symptoms to severe acute respiratory-related problems, including multi-organ failure. The virus is key in COVID-19's pathogenesis, triggering different inflammatory responses. A well-known inflammatory biomarker, C-reactive protein (CRP), has become a possible diagnostic and prognostic marker in COVID-19 patients. This review aims to explain CRP in COVID patients and disease progression. It also shows how it can have a predictive value for clinical outcomes and potential therapeutic purposes. Additionally, we address the limitations and offer recommendations for future CRP studies. Overall, this review underscores the potential of CRP as a promising biomarker for managing COVID-19 and highlights the necessity of further research to understand its clinical significance thoroughly.